Predictors of response to erenumab after 12 months of treatment,Brain and Behavior

当前位置： X-MOL 学术 › Brain Behav. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Predictors of response to erenumab after 12 months of treatment
Brain and Behavior ( IF 3.1 ) Pub Date : 2021-07-16 , DOI: 10.1002/brb3.2260
Carlo Baraldi ₁ , Flavia Lo Castro ₂ , Maria Michela Cainazzo ₃ , Luca Pani _{3,

4,

5,

6} , Simona Guerzoni ₃

Affiliation

Erenumab is a monoclonal antibody acting against calcitonin gene-related peptide receptor and approved for the preventive treatment of chronic migraine. The aim of the present study is to identify clinical predictors of good response in patients with chronic migraine and medication overuse-headache.

中文翻译：